View as an RSS Feed
View Alpha Exposure's Articles BY TICKER:
ParkerVision Still Tremendously Overvalued
- ParkerVision's loss of JMOL on infringement an enormous blow.
- ParkerVision stock now essentially worthless.
- $0.25 per share price target based on option value.
ParkerVision Bulls Vastly Overstating Pre-Judgment Interest Amount
- ParkerVision's pre-judgment interest is likely to disappoint.
- Careful calculation shows Qualcomm owes only $20.5 million in pre-judgment interest.
- ParkerVision remains enormously overvalued.
ParkerVision: Read The Transcript, Short The Stock
- Analysis of the May 1 court transcript reveals significant risks to ParkerVision.
- ParkerVision faces high probability of losing the entire case due to Qualcomm's Non-Infringement JMOL.
- Even a best-case valuation shows ParkerVision is more than 100% overvalued.
FuelCell's Backlog Faces A Steep Cliff
- FuelCell's largest customer (POSCO) is going away.
- Order levels have been too low to offset the POSCO loss and FuelCell is at risk of missing estimates.
- Due to the POSCO loss, we believe FuelCell's cash burn will accelerate.
- Senvest: Better Than Buffett And Einhorn... At A Discount
- Parametric Sound: A Turkey's Desperate Attempt To Avoid The Chopping Block
- Affymax: Emerging Data Supports Conclusion Omontys Likely Dead
- Lee Enterprises: When A Company Burns The Furniture, Investors Should Short The Stock
- The Time To Short ParkerVision Is Now
- Celsion Continues Publishing Meaningless Post-Hoc Data Mined Results
- New Data Show Omontys At Least 4x Worse Than Reported: Now 22 Suspected Deaths
- Suntech Shareholders Face Imminent Doom
- Uni-Pixel Investors Getting Fooled Again
- CVD Equipment - Northland Initiation Basically Cut And Paste From ThinkEquity
- Just Like Omontys.com, Affymax Is Likely To Disappear
- CVD Equipment - Exposing The Truth On The Graphene Hype
- Celsion Misleading Investors ... Again
- CVD Equipment's Defense Shows No Errors In Our Prior Article
- Don't Believe In Affymax - The Stock Is Probably Worthless
- CVD Equipment's Business Is Failing: Don't Fall For The Graphene Hype
- Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen
- Celsion's Bad News: Everyone Gives Up
- Celsion's Coming Dilution: 600% Dilution In Past 5 Years Is Not Enough
- Exact Sciences - Appendix: Answering The Critics
- Exact Sciences - Cologuard Is Strike 3, And EXAS Is Out (5 Of 5)
- Exact Sciences: This Is Not The Next Pap Smear - Debunking The Bull Case (4 of 5)
- Exact Sciences - Line Your Pockets, Not Your Toilet Bowl (3 Of 5)
- Exact Sciences - Flushing $$$ Down The Drain (2 Of 5)
- Exact Sciences - The Rotten Sniff Test (1 Of 5)
- Post-Hoc Analysis Hype Debunked
- Uni-Pixel: Is The SEC Investigating?
- Analysis Of Celsion's Press Release Shows Extended Risks